Visual halluzinations in patients with PD and the Charles-Bonnet- syndrome - A phenomenological and pathogenetic confrontation;Die optischen halluzinationen des Parkinson-patienten und das Charles Bonnet-syndrome. Eine phanomenologische und pathogenetische gegenuberstellung

Fortschritte der Neurologie Psychiatrie

Volumn 68, Issue 3, 2000, Pages 129-136

  Diederich, Nico J ^a,b   Pieri, V ^c   Goetz, C G ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHARLES BONNET SYNDROME; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PATHOGENESIS; PHENOMENOLOGY; VISUAL HALLUCINATION;

AGED; DISEASE PROGRESSION; EMOTIONS; FEMALE; HALLUCINATIONS; HUMANS; MALE; PARKINSON DISEASE; SYNDROME;

EID: 0034019906     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-11619     Document Type: Article

References (83)

1. Tanner CM, Vogel C, Goetz CG, Klawans H. Hallucinations in Parkinson's disease: a population study. Ann Neurol 1983; 14: 136
2. Fasshauer A. Art und Häufigkeit paranoid-halluzinatorischer Psychosen bei Parkinsonpatienten. Akt Neurol 1997; 24: 33
3. Klein C, Kömpf D, Pulkowski V et al. A study of visual hallucinations in patients with Parkinson's disease. J Neurol 1997; 244: 371-377
4. Sanchez-Ramos JR, Ortoll R, Paulsen GW. Visual hallucinations associated with Parkinson's disease. Arch Neurol 1996; 53: 1265-1268
5. Rondot P, de Recondo J, Coignet A, Ziegler M. Mental disorders in Parkinson's disease after treatment with L-dopa. Adv Neurol 1984; 40: 259-269
6. Moskovitz C, Moses H, Klawans HL Levodopa induced psychosis: a kindling phenomenon. Am J Psych 1978; 135: 669-675
7. Goetz CC, Tanner CM, Klawans HL. Pharmacology of hallucinatons induced by long-term drug therapy. Am J Psych 1982; 139: 494-497
8. Graas M, Diederich N. Exogene Psychosen beim Morbus Parkinson und ihre Behandlung mit Clozapin. Nervenheilkunde 1997; 16: 122-131
9. Pappert EJ, Goetz CG, Raman R et al. Severity and temporal stability of hallucinations/illusions in Parkinson's disease: prospective, longitudinal study. Neurol 1997; 48: 370
10. Haeske-Dewick HC. Hallucinations in Parkinson's disease: characteristics and associated features. Int J Geriatr Psych 1995; 10: 487-495
11. Goetz CG, Pappert EJ, Blasucci LM et al. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurol 1998; 50: 515-517
12. De Smet Y, Ruberg M, Serdaru M et al., Confusion, dementia and anticholinergics in Parkinson's disease. J Neuro Neurosurg Psychiatry 1982; 45: 1161-1164
13. Mego G, Bonifati V, Cusimano G et al.. Hallucinations in Parkinson's disease: neuropsychological study. Ital J Neurol Sci 1990; 11: 373-379
14. Naimark D, Jackson E, Rockwell E, Jeste DV. Psychotic symptoms in Parkinson's disease patients with dementia. J Am Geriatr Soc 1996; 44(3): 296-299
15. Scharf B, Moskovitz Ch, Lupton MD, Klawans HL. Dream phenomena induced by chronic levodopa therapy. J Neural Transm 1978; 4: 143-151
16. Nausieda PA, Weiner W, Kaplan L, Weber S, Klawans H. Sleep disruption and psychosis in chronic levodopa therapy. Clin Neuropharmacol 1982; 5: 183-194
17. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment -induced hallucinations. Ann Neurol 1993; 34: 710-714
18. Pappert EJ, Goetz CG, Niederman FG, Raman R, Leurgans S. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord 1999; 14: 117-121
19. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurol 1993; 43: 2227-2229
20. Duvoisin RC Parkinson's disease. A guide for patient and family. New York: Raven, 1991
21. Fénelon G, Mahieux F. Hallucinations in Parkinson's disease: prevalence and risk factors. Mov Disord 1998; 13 (Suppl 2): 190
22. Acheson JF, Sanders MD. Vision. J Neurol Neurosurg Psychiatry 1995; 59: 4-15
23. Farnsworth D. The Farnsworth 100-hue test and dichotomous tests for color vision. J Opt Soc Am 1943; 33: 568-578
24. Smith VC, Pokorny J, Pass AS. Color-axis determination on the Farnsworth-Munsell 100-Hue test. Am J Opthalmol 1985; 100: 176-182
25. Vistech Consultants Inc. VCTS 6500 Instructions Manual. Dayton, Ohio 1988
26. Pelli DG, Robson JG, Wilkins AJ. Designing a new letter chart for measuring contrast sensitivity. Clin Vision Sci 1988; 2: 187-199
27. Diederich NJ, Goetz CG, Raman R et al. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharm 1998; 21: 289-295
28. Pieri V, Diederich NJ, Raman R, Goetz CG. Decreased color and contrast perception in Parkinson's disease. J Neurol Sciences. 1999. (in press)
29. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease: a community-based study. Arch Neurol 1999; 56: 595-601
30. Graham JM, Gruenewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63: 434-440
31. Graham JM, Gruenewald RA, Sagar HJ. The clinical diagnosis of hallucinations in patients with idiopathic Parkinson's disease. Mov Disord 1998; 13 (Suppl 2): 208
32. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatr 1998; 64: 533-535
33. Jimenez-Jimenez FJ, Orti-Pareja M, Gasalla T, Tallon-Barranco A, Cabrera-Valdivia F, Fernandez-Lliria A. Cenesthetic hallucinations in a patient with Parkinson's disease [letter]. J Neurol Neurosurg Psychiatry 1997; 63: 120
34. Clark J. Case history of a patient with musical hallucinations and Parkinson's disease [letter]. Int J Geriatr Psychiatr 1998; 13: 886-887
35. Gold K, Rabins PV. Isolated visual hallucinations and the Charles Bonnet Syndrome: a review of the literature and presentation of six cases. Compr Psychiatry 1989; 30; 90-98
36. Tueth MJ, Cheong JA, Samander J. The Charles Bonnet syndrome: a type of organic visual hallucinosis. J Geriatr Psychiatry Neurol 1995; 8: 1-3
37. Fernandez A, Lichtshein G, Vieweg WV. The Charles Bonnet syndrome: a review. J Nerv Ment Dis 1997; 185: 195-200
38. Gorgens K, Liedtke M. Charles Bonnet syndrome. Psychiatr Prax 1998; 25: 85-86
39. Ey H. Traité des Hallucinations. Paris: Masson, 1973.
40. Teunisse RJ, Cruysberg JR, Hoefnagels WH et al., Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome. Lancet 1996; 347: 794-797
41. Fuchs T. Zur Psychopathologie und Pathogenese des Charles-Bonnet-Syndrom. Fundamenta Psychiatria 1990; 4: 181-185
42. De Morsier G. Le syndrome de Charles Bonnet: Hallucinations visuelles des vieillards sans déficience mentale. Ann Med Psychol 1967; 125: 677-702
43. Sizaret P, Degiovanni E, Degiovanni A et al. Un cas de syndrome de Charles-Bonnet. Revue Otoneuroophthalmologique 1971; 43: 117-121
44. Olbrich HM, Engelmeier MP, Pauleikoff D et al. Visual hallucinations in opthalmology. Graefe's Arch Clin Exp Opthalmol 1987; 225: 217-230
45. Podoll K, Osterheider M, Noth J. Das Charles Bonnet-Syndrom. Fortschr Neurol Psychiatr 1989; 57: 43-60
46. Podoll K, Schwarz M, Noth J. Charles Bonnet-Syndrom bei einem Parkinson-Patienten mit beidseitigem Visusverlust. Nervenarzt 1990; 61: 52-56
47. Sichart V, Fuchs T. Visuelle Halluzinationen bei älteren Menschen mit reduziertem Visus: Das Charles Bonnet-Syndrom. Klin Monatsb Augenheilk 1992; 200: 224-227
48. Nadarajah J. Visual hallucinations and macular degeneration: an example of the Charles Bonnet syndrome. Aust NZJ Ophthalmol 1998; 26: 63-65
49. Pliskin NH, Kiolbasa TA, Towle VL et al. Charles Bonnet-syndrome: an early marker for dementia? J Am Geriatr Soc 1996; 44: 1055-1061
50. Wertheimer J. Some hypotheses about the genesis of visual hallucinations in dementias. In: Katara C and Levy R (Hrsg.). Delusions and hallucinations in old age. London: Royal College of Psychiatrists, 1993. 201-208
51. Lepore FE. Visual loss as a causative factor in visual hallucinations associated with Parkinson's disease [Letter]. Arch Neurol 1997; 54: 799
52. Lepore FE. Spontaneous visual phenomena with visual loss: 104 patients with lesions of retinal and neural afferent pathways. Neurol 1990; 40: 444-447
53. Bodis-Wollner I, Marx MC, Mitra S, Bobak P, Mylin L, Yahr M. Visual dysfunction in Parkinson's disease: loss in spatiotemporal contrast sensitivity. Brain 1987; 11: 1675-1698
54. Price MJ, Feldman RG, Adelberg D, Kaynes H. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurol 1992; 42: 887-890
55. Büttner T, Kuhn W, Müller T, Patzold T, Heidbrink K, Przuntek H. Distorted color discrimination in "de novo" Parkinsonian patients. Neurol 1995; 45: 386-387
56. Büttner T, Kuhn W, Müller T, Welter FL, Federlein J, Heidbrink K, Przuntek H. Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease. J Neural Transm 1996; 103: 1195-1204
57. Haug BA, Kolle RU, Trenkwalder C, Oertel WH, Paulus W. Predominant affection of the blue cone pathway in Parkinson's disease. Brain 1995; 11: 771-778
58. Barrett AM, Crucian GP, Schwartz R, Nallamshetty H, Heilman M. Seeing the trees but not the forest: limited perception of large configurations in Parkinson's disease. Neurol 1999; 52: A183
59. Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurol 1999; 52: 541-546
60. Van der Borght T, Minoshima S, Giordani B et al. Cerebral metabolic differences in Parkinson's disease and Alzheimer's disease matched for dementia severity. J Nucl Med 1997; 38: 797-802
61. Kraft E, Winkelmann J, Trenkwalder C, Auer DP. Visual hallucinations, white matter lesions and disease severity in Parkinson's disease. Acta Neurol Scand 1999; 99: 362-367
62. Howard R, David A, Woodruff P, Mellers I, Wright J, Brammar M, Bullmore E, Williams S. Seeing visual hallucinations with functional magnetic resonance imaging. Dement Geriatr Cogn Disord 1997; 8: 73-77
63. Ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P, Wiliams S. The anatomy of conscious vision: an fMRI study of visual hallucinations. Nat Neurosci 1998; 1: 738-742
64. Freedman SJ, Grunebaum HU, Greenblatt M. Perceptual and cognitive changes in sensory deprivation. In: Salomon P, Leiderman PH, Kubzanski PE, et al. (Hrsg.). Sensory Deprivation. Cambridge: Harvard Press, 1961. 58-71
65. West LJ. Hallucinations. Philadelphia: Grune and Stratton, 1962
66. Rosenzweig N, Gardner N. The role of input relevance in sensory isolation. Am J Psychiatr 1966; 122: 920-928
67. Cogan DG. Visual hallucinations as release phenomena. Graefe's Arch Clin Exp Opthalmol 1973; 188: 139-150
68. Brasic JR. Hallucinations. Percept Mot Skills 1998; 86: 851-877
69. Alroe CJ, McIntyne JNM. Visual hallucinations - the Charles-Bonnet syndrome and bereavement. Med J Australia 1983; 10: 674-675
70. Paulson GW. Visual hallucinations in the elderly. Gerontology 1997; 43: 255-260
71. Roane DM, Rogers JD, Robinson JH, Feinberg TE. Delusional misidentification in association with parkinsonism. J Neuropsychiatry Clin Neurosci 1998; 10: 194-198
72. Manford M, Andermann F. Complex visual hallucinations. Clinical and neurobiological insights. Brain 1998; 121: 1819-1840
73. Jellinger K. New developments in the pathology of Parkinson's disease. [Review]. Adv Neurol 1990; 53: 1-16
74. Pieri V, Diederich N, Comella CL REM sleep behavior disorder in Parkinson's disease patients with an without coexistent hallucinations. Mov Disord 1998; 13 (Suppl 2): 274
75. Goetz CG. Hallucinations in Parkinson's disease: the clinical syndrome. Adv Neurol 1999; 80: 419-423
76. Perry EK, Perry RH. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain and Cognition 1995; 28: 240-258
77. Heinz A, Przuntek H, Winterer G, Pietzcker A. Klinik und Verlauf dopamininduzierter Psychosen unter kontinuierlicher dopaminerger Therapie und ihre Implikationen für die Dopaminhypothese schizophrener Symptomatik. Nervenarzt 1995; 66: 662-669
78. Gil R, Creange A, Degos JD, Adle-Biassette H, Gray F. Confrontation de la Salpêtrière. Syndrome parkinsonien, hallucinations et démence chez une femme de 70 ans. Rev Neurol 1997; 153: 440-447
79. Schultz DW, Lennox GG, Ironside JW, Warlow CP. Behavioural disturbance and visual hallucinations in a 78 year old man. J Neurol Neurosurg Psychiatry 1998; 65: 933-938
80. Litvan I, MacIntyre A, Goetz CG et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson's disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 1998; 55: 969-978
81. Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurol 1998; 51: 811-814
82. Pankow L, Pliskin N, Luchins D. An optical Intervention for visual hallucinations associated with visual impairment and dementia in elderly patients. J Neuropsychiatry 1996; 8: 88-92
83. Ala TA, Yang KH, Sung JH, Frey WH. Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study. J Neurol Neurosurg Psychiatry 1997; 62: 16-21